Dr. Hill is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
6565 Fannin St
Houston, TX 77030Phone+1 714-441-1450Fax+1 713-790-8750
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2014 - 2017
Vanderbilt University Medical CenterResidency, Internal Medicine, 2011 - 2014
University of Texas Medical Branch School of MedicineClass of 2011
Certifications & Licensure
TX State Medical License 2015 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Inductee Alpha Omega Alpha Honor Medical Society, 2011
Clinical Trials
- Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells Start of enrollment: 2021 Aug 02
Publications & Presentations
PubMed
- 1 citationsImpact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL.Ibrahim Aldoss, Gregory W Roloff, Rawan Faramand, Noam E Kopmar, Chenyu Lin
Blood Advances. 2024-12-10 - Efficacy of Letermovir for Cytomegalovirus Prophylaxis Following Alemtuzumab T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplant.Ibrahim N Muhsen, Kristen E Shaver, Tao Wang, Mengfen Wu, Premal Lulla
Transplantation and Cellular Therapy. 2024-12-01 - Gastrointestinal involvement refines prognosis in minnesota standard risk acute graft-vs.-host disease.Curtis M Marcoux, Amin M Alousi, Jin Im, Laquisa C Hill, Portia Smallbone
Bone Marrow Transplantation. 2024-11-01
Press Mentions
CAR T Cells Produce Complete Responses in T-cell MalignanciesJanuary 7th, 2020
Stand up to Cancer Dream Team Tackles T-cell Lymphoma, Focused on CAR-Based StrategiesJanuary 28th, 2019- CAR T Cell Therapy for T Cell Lymphoma Shows Promise in Phase I TrialJanuary 6th, 2024
- Join now to see all
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
